Asia Deal Watch: Astellas Looks To Vector Cell Tech From Japan’s RiKen In Oncology
RiKen gets $9.3m up front plus potential milestones and royalties for use of its aAVC technology, while retaining research rights to the platform. JW Pharmaceutical acquires Vietnam’s Euvipharm.
